From hours to minutes? Genentech says Ocrevus subcutaneous formulation works just as well as IV
To receive Roche’s multiple sclerosis drug Ocrevus, patients currently have to sit through two to four hours of infusion every six months. A year ago …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
